Jason Blum and James Wan’s merged horror operation now has a shared name: Blumhouse Atomic. The new identity sits above Blumhouse and Atomic Monster, which will continue to operate as distinct production labels with their own creative teams developing film and television projects.

That distinction is the important part of the announcement. This is not being presented as the disappearance of either name from the production side. Instead, Blumhouse Atomic is the corporate umbrella for two labels with established identities, creative relationships and genre portfolios. The structure gives the companies a collective banner while preserving the individual lanes through which their projects are made.

For horror fans, the rebrand formalizes a partnership that began with the 2024 merger of Blumhouse and Atomic Monster. It also puts a clean name on an increasingly wide business: one built around movies and television now openly looking toward games and live experiences as possible ways to extend its horror properties.

A new umbrella, not a single replacement label

Production-label language can sound more cosmetic than consequential, but it explains who is expected to make decisions and how projects may be positioned. Under the announced arrangement, Blumhouse and Atomic Monster remain the labels associated with individual films and television series. Blumhouse Atomic becomes the shared identity above them.

In practical terms, that means the company can present a combined strategy and scale without requiring every creative team to work as though it were part of one undifferentiated studio unit. For a genre business, that can matter. Horror encompasses everything from franchise sequels to smaller original concepts, and those projects may demand very different creative development processes even when they benefit from common resources.

Blum described the new name as the next step after the merger, pointing to the group’s collection of recognizable horror properties. Wan’s associated franchises include The Conjuring, Insidious and Saw, while the new company is framing the combined operation as a place where established series and newer creators can coexist.

The company has also said a new Saw chapter is in development and characterized its return to Wan as an example of the opportunities created by the combined organization. The announcement does not provide a release date, cast, creative team or story details for that chapter, so it is best understood as confirmation of the project’s direction rather than a complete production update.

The numbers behind the strategy

Blumhouse Atomic says the combined banners have generated more than $2.5 billion at the worldwide box office against combined production budgets below $330 million. Those figures underline the business model the company is emphasizing: make genre films economically enough that a hit does not need blockbuster-scale spending to be meaningful.

Related coverage includes Blumhouse Atomic Unites Wan and Blum’s Horror Empire.

Its 2026 results are central to that message. The company says it brought in $1.3 billion during the year, aided by Curry Barker’s Obsession, which reached $520 million worldwide, and Kane Parsons’ Backrooms, which reached $400 million worldwide.

Box office is not the same thing as profit, and the supplied figures do not establish profitability for any individual film. Worldwide gross is the total ticket revenue reported from theatrical exhibition; it does not by itself reveal marketing expenses, revenue splits, distribution costs or the final financial return to a production company. Even so, the stated gap between aggregate box-office performance and production spending illustrates why low- and mid-budget horror remains attractive: relatively contained production costs can make a broad theatrical response especially valuable.

That financial discipline is not merely a talking point for Blumhouse Atomic. Sam Zimmerman was appointed senior vice president of development and acquisitions with a remit to build genre features budgeted below $5 million. The company has also entered a first-look agreement with Divide/Conquer focused on high-concept projects made at an economical cost.

A first-look deal generally gives one company the first opportunity to evaluate projects from a partner before those projects are offered elsewhere. The announcement identifies the goal here—economical, high-concept work—but does not spell out which specific films will emerge from the arrangement.

Why the focus on emerging filmmakers matters

Wan has positioned new creative voices as a major part of Blumhouse Atomic’s purpose, naming Kane Parsons, Curry Barker, Josh Giuliano and Dylan Clark among the filmmakers the company wants to support over time. That is a useful complement to the franchise-heavy side of the slate.

Franchises offer built-in recognition, but original horror concepts can create the next recognizable property. A model that pairs smaller-budget development with a willingness to work repeatedly with filmmakers may give the company more ways to identify ideas that can grow. The stated aim is not just to make a single film with a new director, but to build relationships that continue after one project.

There is also a creative reason that a lower-budget mandate can fit horror particularly well. The genre can draw tension from restricted spaces, suggestion, sound, editing, unusual imagery and a sharply defined premise. None of those tools require a massive budget by definition. A low budget is not automatically an artistic advantage, of course; it can limit shooting days, locations and effects work. But the announcement makes clear that Blumhouse Atomic sees disciplined spending as compatible with commercial ambition.

The company’s use of the term high concept is worth unpacking too. In film development, it generally refers to an idea that can be quickly communicated and understood—often a premise with a strong hook. That does not tell audiences what any particular Divide/Conquer project will be, but it does describe the kind of pitch Blumhouse Atomic is seeking: immediately legible concepts that can stand out without necessarily requiring enormous scale.

Games are named as an opportunity, not a slate

For readers who follow games as closely as film, the most notable forward-looking detail may be Blum’s reference to opportunities beyond theaters, including television, games and live experiences. It signals that the company sees its horror stories as potentially cross-media properties rather than as theatrical releases alone.

However, the announcement does not reveal a game, developer, platform, release window or adaptation plan. There is no basis here to treat any listed film franchise as having a confirmed game in production. The relevant takeaway is strategic: games are now explicitly within the company’s stated growth ambitions.

That matters because horror’s strengths can translate naturally between formats—atmosphere, rules-based threats, iconic monsters and mystery—but a corporate interest in games is still very different from a finished development agreement. Any future game news will need to establish its own details, including who is making it and how directly it connects to the film side.

The broader games business continues to turn on long development cycles and evolving creative plans, something reflected in industry updates such as the formal naming of The Elder Scrolls 6: Sentinel. Blumhouse Atomic’s statement is far earlier and less specific than that kind of product announcement: it establishes interest in the medium, not a title consumers can anticipate on a release calendar.

The announced 2027 slate

Blumhouse Atomic has listed a sizable 2027 film slate: River, The Revenge of La Llorona, The Exorcist: Martyrs, Anything But Ghosts, Paranormal Activity, Molepeople, Blair Witch, Sleepover and Seasons.

The lineup indicates a mixture of familiar horror names and titles that, based on the announcement, have not yet been explained in detail. Several entries clearly evoke established franchises, while others are simply names at this stage. No dates within 2027, plot descriptions, formats or label assignments are provided for the slate, so readers should avoid assuming release order or whether any title will be a theatrical film, streaming release or something else until additional information is announced.

Still, the list communicates the scale of the company’s plans. A broad slate lets a horror producer balance recognizable brands with newer ideas, potentially reducing the pressure for any one project to carry an entire year. The new Blumhouse Atomic banner gives that range a single public identity while leaving the two underlying labels in place.

What the name change actually signals

Blumhouse Atomic is less a simple logo swap than a statement of how Blum and Wan want their merged business to be understood. The organization is combining a claimed track record of economical production, global box-office reach, established horror franchises and a development push aimed at filmmakers working at smaller budget levels.

Its next test will be execution. The company has an announced 2027 slate, a stated intention to cultivate creators for the long term, a first-look relationship intended to find cost-effective concepts and ambitions in games and live experiences. But the immediate, concrete change is organizational: Blumhouse and Atomic Monster are now housed under Blumhouse Atomic, while continuing to make projects as separate labels.